Brief: Hanx Biopharmaceuticals (Wuhan) Says HX111 Received Approval For Clinical Trials In China
23/12/2025 15:37
Dec 23 (Reuters) - Hanx Biopharmaceuticals (Wuhan) Co Ltd 3378.HK: HX111 RECEIVES APPROVAL FOR CLINICAL TRIALS IN CHINA FROM NMPA Further company coverage: 3378.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanx Biopharmaceuticals (Wuhan)
See all newsBrief: Hanx Biopharmaceuticals (Wuhan) Enters Agreement To Explore AI For Science In Drug Research
Brief: Hanx Biopharmaceuticals (Wuhan)Enters Agreement To Establish Joint Ai-Driven Drug Discovery Lab
Brief: Hanx Biopharmaceuticals (Wuhan) And Twinedge Bioscience Initiates Research Collaboration
Farmers in biggest cocoa producer are very short of fertilizer, survey says
Brief: Hanx Biopharmaceuticals (Wuhan) Says Xiao Jieyu Re-Designated As Executive Director